DDFC
DDFC Brand names, DDFC Analogs
DDFC Brand Names Mixture
- No information avaliable
DDFC Chemical_Formula
C9H11F2N3O4
DDFC RX_link
http://www.rxlist.com/cgi/generic/gemcitab.htm
DDFC fda sheet
DDFC msds (material safety sheet)
DDFC Synthesis Reference
No information avaliable
DDFC Molecular Weight
263.198 g/mol
DDFC Melting Point
168.64oC
DDFC H2O Solubility
Soluble
DDFC State
Solid
DDFC LogP
-1.318
DDFC Dosage Forms
Lyophilized powder for injection
DDFC Indication
For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.
DDFC Pharmacology
Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.
DDFC Absorption
100%
DDFC side effects and Toxicity
Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD50=500 mg/kg (orally in mice and rats)
DDFC Patient Information
General �� Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.
Laboratory Tests �� Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.
Laboratory Tests �� Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.
DDFC Organisms Affected
Humans and other mammals
